Saturday 17 October 2026 Export PEPG’s income statement to Excel — free account

PepGen, Inc.

In the quarter to June 2026, EPS grew 62.9% and free cash flow grew 33.0%, each against the same quarter a year earlier.

2.60 0.07 +2.77%

Follow PEPG

Alert me

Market cap: $175.2M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.06

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	3	—	1	—	—	—	—	—

Insider Ownership 10.70%

Capital & Financial Ratios $m

Market Cap 175.22

Revenue —

Net Income (71.94)

Free Cash Flow (69.50)

Net Debt (117.24)

Current Ratio 13.36

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 1.51

Past 5Y EPS Growth —

This Y EPS Growth 48.91%

Next Y EPS Growth (2.14%)

Next Y revenue growth —

Next 5Y EPS Growth 21.56%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 64.78%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	110	120	148	117
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	113	124	151	120

	2023	2024	2025	Q'26
Payables	1	2	1	1
ST’ Debt	—	—	—	—
Other	—	—	—	—
	18	17	13	9

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	(6.37%)

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(18)	(16)	—	—	—
’25	(23)	(24)	(19)	(16)	(82)
’24	(23)	(16)	(24)	(19)	(82)
’23	(15)	(17)	(17)	(19)	(69)
’22	(12)	(13)	(21)	(13)	(59)
’21	(3)	(6)	(8)	(6)	(23)
’20	—	—	—	(2)	(2)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(18)	(16)	—	—	—
’25	(23)	(24)	(19)	(16)	(82)
’24	(23)	(16)	(24)	(20)	(83)
’23	(17)	(18)	(17)	(20)	(72)
’22	(14)	(13)	(21)	(14)	(63)
’21	(3)	(6)	(8)	(6)	(23)
’20	—	—	—	(2)	(2)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.26)	(0.26)	—	—	—
’25	(0.92)	(0.70)	(0.52)	(0.27)	(2.12)
’24	(0.63)	(0.87)	(0.66)	(0.68)	(2.85)
’23	(0.69)	(0.82)	(0.98)	(0.82)	(3.30)
’22	(18.94)	(1.23)	(0.79)	(0.96)	(4.42)
’21	(7.42)	(6.03)	(9.07)	(7.75)	(30.28)
’20	—	—	—	—	(2.17)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	—	4.32	3.72	2.90	0.88	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	—	17.81	20.00	19.30	6.72
People
People	Employees	—	—	—	—	—	31	45	64	81	56
	Revenue/emp, $m	—	—	—	—	—	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	—	—	—	0.00	0.00	0.00	0.00	—	—	—
	EBT	—	—	—	(1)	(2)	(27)	(65)	(79)	(91)	(90)
	EBT margin, %	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	—	—	—	(1)	(2)	(27)	(69)	(79)	(90)	(90)
	Depreciation	—	—	—	0	0	0	0	1	1	3
Per share, $
Per share, $	Revenue	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	—	—	—	(0.06)	(2.17)	(30.28)	(4.42)	(3.30)	(2.85)	(2.12)
	Cash flow	—	—	—	(0.04)	(1.90)	(25.08)	(3.79)	(2.90)	(2.61)	(1.93)
	Capex	—	—	—	0.00	(0.01)	(0.55)	(0.24)	(0.11)	(0.02)	(0.01)
	Free cash flow	—	—	—	(0.04)	(1.91)	(25.64)	(4.03)	(3.01)	(2.62)	(1.94)
	Book value	—	—	—	0.17	(7.31)	(35.61)	11.49	4.56	3.76	3.49
	Shares, m	—	—	—	22	1	1	16	24	32	42
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	—	—	—	(1)	(2)	(23)	(59)	(69)	(82)	(82)
	Capex	—	—	—	0	0	0	(4)	(3)	0	0
	Free cash flow	—	—	—	(1)	(2)	(23)	(63)	(72)	(83)	(82)
Balance, $m
Balance, $m	Working capital	—	—	—	3	9	130	167	95	107	138
	Total debt	—	—	—	—	—	—	25	—	—	—
	Net debt	—	—	—	(3)	(10)	(133)	(182)	(110)	(120)	(148)
	Shareholders’ equity	—	—	—	4	(6)	(32)	180	108	119	147
Returns, %
Returns, %	ROA	—	—	—	0.00	(54.96)	(35.36)	(38.28)	(43.62)	(61.23)	(55.21)
	ROIC	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	—	—	—	0.00	327.08	141.93	(93.67)	(54.59)	(79.26)	(67.39)

Negative figures in brackets.

All 10 years →

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
UPB Upstream Bio, Inc.	$184.6M	— (loss-making)	— (loss-making)	−17.50% (below 0%: shrinking)	n/m	+9.33% (above 0%: growing)	100.00%	(5,480.98%)	Compare
ELDN Eledon Pharmaceuticals, Inc.	$184.5M	— (loss-making)	—	—	n/m	−28.02% (below 0%: shrinking)	0.00%	0.00%	Compare
SION Sionna Therapeutics, Inc.	$184.5M	— (loss-making)	—	—	n/m	−22.40% (below 0%: shrinking)	—	0.00%	Compare
ACOG Alpha Cognition Inc.	$184.0M	— (loss-making)	—	+267.56% (above 0%: growing)	n/m	−109.25% (below 0%: shrinking)	94.80%	(127.29%)	Compare
BCYC Bicycle Therapeutics PLC Sponsored ADR	$181.4M	— (loss-making)	— (loss-making)	−78.46% (below 0%: shrinking)	n/m	+31.95% (above 0%: growing)	100.00%	(8,673.93%)	Compare
PEPG PepGen, Inc.	$175.2M	— (loss-making)	—	—	n/m	+33.02% (above 0%: growing)	0.00%	0.00%
ORMP Oramed Pharmaceuticals Inc.	$173.9M	1.0×	— (loss-making)	+193.26% (above 0%: growing)	+493.75% (above 0%: growing)	+94.29% (above 0%: growing)	0.65%	0.00%	Compare
WHWK Whitehawk Therapeutics, Inc.	$173.3M	— (loss-making)	— (loss-making)	+33.48% (above 0%: growing)	n/m	+72.57% (above 0%: growing)	89.36%	0.00%	Compare
DTIL Precision BioSciences, Inc.	$170.3M	— (loss-making)	— (loss-making)	+37,272.41% (above 0%: growing)	n/m	+33.73% (above 0%: growing)	100.00%	0.00%	Compare
Median of peers	$182.7M	—	—	+113.37%	—	+20.64%	94.80%	0.00%

All 614 Biotechnology stocks →

PepGen, Inc. (PEPG) key facts

PepGen, Inc. (PEPG) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, PEPG traded at $2.60, a market capitalization of $175.2 million.
Return on equity was −67.4% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.